Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study

IMPORTANCE: Atezolizumab (anti–programmed death ligand 1) has demonstrated safety and activity in advanced and metastatic urothelial carcinoma, but its long-term clinical profile remains unknown. OBJECTIVE: To report long-term clinical outcomes with atezolizumab therapy for patients with metastatic...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:JAMA Oncol
Autores principales: Petrylak, Daniel P., Powles, Thomas, Bellmunt, Joaquim, Braiteh, Fadi, Loriot, Yohann, Morales-Barrera, Rafael, Burris, Howard A., Kim, Joseph W., Ding, Beiying, Kaiser, Constanze, Fassò, Marcella, O’Hear, Carol, Vogelzang, Nicholas J.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Medical Association 2018
Materias:
Original Investigation
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5885219/
https://ncbi.nlm.nih.gov/pubmed/29423515
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.5440
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares